Table 1 Baseline characteristics of patients with and without at least one platelet transfusion with poor response
Variables | All patients n = 181 | Patients with at least one PT with poor response n = 141 | Patients without poor PT response n = 40 | P value | |
|---|---|---|---|---|---|
Demographic characteristics | |||||
Age, years | 60 (48–68) | 60 (46–67) | 66 (56–73) | 0.0109 | |
Male sex | 103 (56.9%) | 77 (54.6%) | 26 (65.0%) | 0.2415 | |
Pregnancya | 55 (33.1%) | 46 (35.4%) | 9 (25.0%) | 0.2414 | |
BMI | 24.9 (22.7–28.4) | 25.0 (22.4–28.4) | 24.8 (23.2–28.1) | 0.5492 | |
History of platelet transfusionb | 76 (63.9%) | 64 (65.3%) | 12 (57.1%) | 0.4798 | |
Cardiovascular disease | 48 (26.5%) | 35 (24.8%) | 13 (32.5%) | 0.3316 | |
Diabetes mellitus | 21 (11.6%) | 15 (10.6%) | 6 (15.0%) | 0.4157 | |
Haematological malignancy | 96 (53.0%) | 85 (60.3%) | 11 (27.5%) | 0.0002 | |
Solid neoplasia | 32 (17.7%) | 26 (18.4%) | 6 (15.0%) | 0.6147 | |
Chemotherapy | 93 (51.4%) | 85 (60.3%) | 8 (20.0%) | < 0.0001 | |
Chronic respiratory disease | 18 (9.9%) | 14 (9.9%) | 4 (10.0%) | 1.0000 | |
Chronic kidney injury | 7 (3.9%) | 3 (2.1%) | 4 (10.0%) | 0.0435 | |
Anti-platelet agents | 24 (13.3%) | 16 (11.3%) | 8 (20.0%) | 0.1544 | |
Type of admission | |||||
Post-operative admission | 32 (15.4%) | 22 (13.3%) | 10 (23.8%) | ||
Medical admission | 176 (84.6%) | 144 (86.7%) | 32 (76.2%) | ||
Post-operative admission | 23 (12.7%) | 14 (9.9%) | 9 (22.5%) | 0.0351 | |
Primary ICU admission diagnosis sepsis | 66 (36.5%) | 59 (41.8%) | 7 (17.5%) | 0.0048 | |
Diagnosis at ICU admission | 0.0109 | ||||
Respiratory distress | 29 (16.0%) | 24 (17.0%) | 5 (12.5%) | ||
Trauma with brain injury | 3 (1.7%) | 0 (0.0%) | 3 (7.5%) | ||
Trauma without brain injury | 1 (0.6%) | 1 (0.7%) | 0 (0.0%) | ||
Neurologic | 11 (6.1%) | 8 (5.7%) | 3 (7.5%) | ||
Acute kidney injury | 1 (0.6%) | 1 (0.7%) | 0 (0.0%) | ||
Cardiovascular | 8 (4.4%) | 5 (3.5%) | 3 (7.5%) | ||
Haematologic | 15 (8.3%) | 12 (8.5%) | 3 (7.5%) | ||
Uro-digestive | 3 (1.7%) | 2 (1.4%) | 1 (2.5%) | ||
Haemorrhage | 12 (6.6%) | 7 (5.0%) | 5 (12.5%) | ||
Metabolic | 3 (1.7%) | 2 (1.4%) | 1 (2.5%) | ||
Other | 29 (16.0%) | 20 (14.2%) | 9 (22.5%) | ||
Patient ABO Groupc | |||||
A | 73 (42.7%) | 60 (44.4%) | 13 (36.1%) | 0.5711 | |
O | 73 (42.7%) | 54 (40.0%) | 19 (52.8%) | ||
B | 21 (12.3%) | 17 (12.6%) | 4 (11.1%) | ||
AB | 4 (2.3%) | 4 (3.0%) | 0 (0.0%) | ||
Rhesus positived | 150 (87.7%) | 120 (88.2%) | 30 (85.7%) | 0.7727 | |
Clinical and laboratory findings at ICU admission | |||||
SAPS IIe | 52 (40–65) | 52 (41–65) | 51 (37–63) | 0.3854 | |
Platelet count, × 109/L | 34 (16–70) | 27 (12–59) | 58 (34–143) | 0.0001 | |
Haemoglobin, g/dl | 8.8 (7.5–10.5) | 8.5 (7.4–9.9) | 11.3 (8.7–13.4) | < 0.0001 | |
Prothrombin time < 70%f | 122 (70.9%) | 97 (73.5%) | 25 (62.5%) | 0.1801 | |
Clinical outcomes | |||||
Number of RBC units transfused | 0 (0–3) | 0 (0–3) | 0 (0–3) | 0.5151 | |
ICU LOS, days | 11 (5–21) | 10 (5–21) | 11 (4–19) | 0.9632 | |
Hospital LOS, days | 24 (12–45) | 24 (12–47) | 24 (11–36) | 0.3293 | |
MV duration, days | 4 (0–11) | 3 (0–11) | 5 (0–12) | 0.5245 | |
Survival at ICU discharge | 133 (73.5%) | 104 (73.8%) | 29 (72.5%) | 0.8735 | |